StreetAlpha.app
Home › Stocks › CAPR

Capricor Therapeutics, Inc. (CAPR)

Healthcare
$7.59
▲ +0.80%
LAST CLOSE · NOV 20

Capricor Therapeutics is a San Diego biotechnology company developing a cell therapy for Duchenne muscular dystrophy. It last closed at $7.59 on Nov 20, up 0.80% on the day. The next earnings report for CAPR is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, CAPR reported EPS of -$0.73. Over its last 8 reports the stock moved an average of 16.7% the session after earnings. Over the last 12 months CAPR insiders bought $0 of stock on the open market and sold $8.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is CAPR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CAPR.

Key Stats

Fiscal 2025
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$105.0M
EPS (diluted)
−$2.26
Free cash flow
−$72.7M
Valuation
Market cap
$441.3M
58.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$44.3M
At Sep 30
Shareholder equity
$209.8M
Shares outstanding
58.1M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $245K$245KFY2021FY2022: $2.6M$2.6MFY2022FY2023: $25.2M$25.2MFY2023FY2024: $22.3M$22.3MFY2024FY2025: $0$0FY2025

From CAPR's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 10).

Next report
Mar 11
Estimated date · After the close
Reported EPS
-$0.73
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How CAPR moved after its last 8 reports
Average move the session after a report ±16.7%
Nov 10, 2026After the close+26.5%
Aug 13, 2026After the close+58.0%
May 12, 2026After the close−3.8%
Mar 12, 2026After the close−8.7%
Nov 10, 2025After the close+11.5%
Aug 11, 2025After the close+2.9%
May 13, 2025After the close+5.1%
Mar 19, 2025After the close+17.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CAPRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CAPR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CAPR

Technical Analysis

CAPR · as of the Nov 20 close · updated each morning
Moving sideways

The stock is 7% below its 20 day and 6% below its 50 day average. It is 159% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 46). The nearest support is the swing low (Oct 5) at $7.37, and the nearest resistance the Pivot at $7.77.

Short trendNeutral
Long trendBearish
MomentumFading
StretchNormal
VolatilityHigh, 13.8%/day
Key levels
$40.3752 week high+431.9%
$19.65200 day average+158.9%
$9.84100 day average+29.6%
$8.29Swing high (Aug 18)+9.2%
$8.16Pivot R1+7.5%
$8.1320 day average+7.1%
$8.0250 day average+5.7%
$7.77Pivot+2.4%
$7.59Last close
$7.37Swing low (Oct 5)−2.9%
$7.20Pivot S1−5.1%
$2.9652 week low−61.0%
Indicators
RSI (14)46.13Middle of its rangeNeutral
MACD0.17Below its signal lineBearish
Stochastic22.3Middle of its rangeNeutral
ADX (14)27.0Trending up
Williams %R-89.2Oversold below −80, overbought above −20Oversold
CCI (20)-21.1Oversold below −100, overbought above 100Neutral
Rate of change−15.7%Change over 10 sessionsBearish
ATR (14)$1.05Typical daily range, 13.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CAPR

What happened before

See how CAPR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CAPR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CAPR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CAPRHow many large options trades hit CAPR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

CAPR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●94 buying vs 85 selling
  • ▲Held by funds +1.8 pts
  • ▼Funds holding -11
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding159170−6.5%
In funds' top 1003−100.0%
Held by funds69.3%67.5%+1.8 pts
New / increased35 / 5926 / 71−3.1%
Reduced / sold out38 / 4745 / 35+6.3%
Put/call ratio0.660.46+43.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CAPR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CAPR Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$8.4M10 sales · 3 insiders
82% of the selling was under pre-arranged trading plans.
2026-03 sold $1.5M2026-04 sold $3.8M2026-05 sold $1.6M2026-06 sold $1.5MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 25Karen KrasneyEvp, General CounselSale24,100$30.38$732K
Jun 25Anthony BergmannCFOSale24,100$30.38$732K
Jun 24Karen KrasneyEvp, General CounselSale900$30.00$27K
Jun 24Anthony BergmannCFOSale900$30.00$27K
May 1Karen KrasneyEvp, General CounselSale plan25,000$31.70$793K
May 1Anthony BergmannCFOSale plan25,000$31.70$793K
Every insider buy and sale for CAPR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CAPR insider trades →

From SEC Form 4 filings by CAPR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CAPR is in one of them and how their past CAPR trades turned out.

CAPR in the AI portfolios
Loading…

CAPR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CAPR in an article yet. Here's the latest on the wider market.

CAPR in the news

CAPR Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Aug 6
Who traded CAPR · since 2017
Latest 2 filings
$1K – $15KTraded Jul 27, 2017Filed Aug 6, 2018
$1K – $15KTraded Jul 27, 2017Filed Aug 6, 2018
PersonTypeAmountTradedFiledDelay
Roger MarshallR · KSSell$1K – $15KJul 27, 2017Aug 6, 2018375 d
Roger MarshallR · KSBuy$1K – $15KJul 27, 2017Aug 6, 2018375 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Capricor Therapeutics

Capricor Therapeutics is a biotechnology company based in San Diego, California. It is developing Deramiocel, a cell therapy for Duchenne muscular dystrophy, a rare genetic disease that causes progressive muscle loss and weakness. The company is also studying a platform built on exosomes, which are small vesicles released by cells, for other possible diseases. It has no approved products yet, and its target patients are people living with this condition.

Headquarters
San Diego, CA